Cargando…
Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
BACKGROUND: Hu-rhEGF-rP64k/Mont is a biotechnology product for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen epidermal growth factor (EGF), which prevents its bin...
Autores principales: | Xing, Puyuan, Wang, Hongyu, Yang, Sheng, Han, Xiaohong, Sun, Yan, Shi, Yuankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902871/ https://www.ncbi.nlm.nih.gov/pubmed/29661145 http://dx.doi.org/10.1186/s12865-018-0249-9 |
Ejemplares similares
-
Enhancement of Skin Wound Healing by rhEGF-Loaded Carboxymethyl Chitosan Nanoparticles
por: Zhang, Pei, et al.
Publicado: (2020) -
rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects
por: Kim, Ji Min, et al.
Publicado: (2020) -
rhEGF-Loaded Hydrogel in the Treatment of Chronic Wounds in Patients with Diabetes: Clinical Cases
por: de Oliveira, Beatriz Guitton Renaud Baptista, et al.
Publicado: (2022) -
Immuno-modulatory effect of local rhEGF treatment during tissue repair in diabetic ulcers
por: García-Honduvilla, Natalio, et al.
Publicado: (2018) -
Responsive Cells for rhEGF bioassay Obtained through Screening of a CRISPR/Cas9 Library
por: Qin, Xi, et al.
Publicado: (2019)